TRPM2 and breast adenocarcinoma: In the present study, we investigated the chemotherapeutic effects produced in breast adenocarcinoma cells via TRPM2 inhibition or RNAi silencing, with a particular focus on cell death pathways, DNA damage levels, and the ability of TRPM2 inhibition to enhance the cytotoxicity of currently used chemotherapeutic agents-of-choice in different molecular subtypes of breast cancer.